References
- Geginat J, Paroni M, Facciotti F, et al. The CD4-centered universe of human T cell subsets. Semin Immunol 2013;25:252–262.
- Klebanoff CA, Gattinoni L, Restifo NP. CD8 + T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211:214–224.
- Weng NP, Araki Y, Subedi K. The molecular basis of the memory T cell response. Nat Rev Immunol 2012;4:306–315.
- Sallusto F, Lenig D, Forester, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708–712.
- Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T cell population mediate highly effective adoptive immunotherapy?. J Immunother 2012;35:651–660.
- Henson SM, Riddell NE, Akbar AN. Properties of end-stage human T cells defined by CD45RA re-expression. Curr Opin Immunol 2012;24:476–481.
- Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167–1174.
- Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804–811.
- Darrasse-Jeze G, Bergot AS, Durgeau A, et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create dominant tolerogenic environment for tumors in mice. J Clin Invest 2009;119: 2648–2662.
- Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis and survival in colorectal cancer. N Engl J Med 2005;353:2654–2666.
- Clave E, Douay C, Coman T, et al. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis. Leuk Lymphoma 2014;55:1788–1795.
- Sukumar M, Liu J, Ji Y, et al. Inhibiting glycolytic metabolism enhances CD8 + T cell memory and anti tumor function. J Clin Invest 2013;123:4479–4488.
- Muralidharan S, Hanley PJ, Liu E, et al. Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. J Immunol 2011;187:5221–5232.
- Bjorklund CC, Ma W, Wang ZQ, et al. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 2011;286:11009–11020.
- Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–1791.